Intravenous Sodium Thiosulfate: Indications, Dosing, and Monitoring
Intravenous sodium thiosulfate is indicated for two primary clinical scenarios: (1) acute life-threatening cyanide poisoning (as sequential therapy with sodium nitrite), and (2) prevention of cisplatin-induced ototoxicity in pediatric cancer patients with non-metastatic disease.
Primary Indications
1. Cyanide Poisoning (FDA-Approved)
Administer sodium thiosulfate immediately following sodium nitrite for acute cyanide poisoning that is serious or life-threatening 1.
Dosing Regimens:
Adults:
- 50 mL (12.5 g) IV immediately after sodium nitrite administration
- Infuse over several minutes following the sodium nitrite dose 1
Pediatric Patients:
- 1 mL/kg body weight (250 mg/kg or approximately 30-40 mL/m² BSA)
- Maximum dose: 50 mL
- Administer immediately after sodium nitrite 1
Redosing: If signs of cyanide poisoning reappear, repeat using one-half the original dose of both sodium nitrite and sodium thiosulfate 1.
Clinical Context for Cyanide Poisoning:
Suspect cyanide poisoning in:
- Structure fire victims exposed to smoke in enclosed areas
- Patients with soot around mouth, nose, or oropharynx
- Altered mental status with metabolic acidosis
- Plasma lactate ≥10 mmol/L in smoke inhalation victims 1
Critical caveat: Sodium thiosulfate is chemically incompatible with hydroxocobalamin and must not be administered through the same IV line 1. The 2023 AHA guidelines recommend hydroxocobalamin as first-line for cyanide poisoning, with sodium nitrite as an alternative when hydroxocobalamin is unavailable, and sodium thiosulfate as reasonable adjunctive therapy to either 2.
2. Prevention of Cisplatin-Induced Ototoxicity (Pediatric Cancer)
The 2020 Lancet Child & Adolescent Health guideline provides the most authoritative recommendations 3:
Strong Recommendation:
Use sodium thiosulfate for children and adolescents with non-metastatic hepatoblastoma receiving cisplatin 3.
Weak Recommendation:
Consider sodium thiosulfate for pediatric patients with other non-metastatic cancers receiving cisplatin 3.
Weak Recommendation Against:
Avoid sodium thiosulfate in patients with metastatic cancers due to uncertain effects on survival 3.
Dosing Protocol (Based on SIOPEL 6 and ACCL0431 Trials):
- Dose: 16-20 g/m² IV
- Timing: 15-minute infusion starting exactly 6 hours after completion of cisplatin infusion
- Cisplatin constraint: Cisplatin infusion duration must be ≤6 hours 3
Critical timing requirement: The 6-hour delay is essential to avoid interfering with cisplatin's antitumor activity. This timing was protocol-specified in both pivotal trials and should not be altered 3.
Evidence Quality:
The SIOPEL 6 trial demonstrated hearing loss in 33% with sodium thiosulfate versus 63% without (p=0.002), with favorable survival outcomes (3-year overall survival 98% vs 92%) 3. The ACCL0431 trial showed hearing loss in 29% with sodium thiosulfate versus 56% without (p=0.0002) 3.
Important limitation: No data exist for patients with pre-existing hearing loss; efficacy in preventing further deterioration is unknown 3.
Off-Label Use: Calciphylaxis
While not FDA-approved, sodium thiosulfate is widely used for calciphylaxis in dialysis patients, though evidence is limited to case series and observational studies 4, 5, 6.
Typical regimen for hemodialysis patients:
- 25 g IV three times weekly after dialysis sessions
- Duration: Variable (months to years based on clinical response) 5, 6
Pharmacokinetic considerations: Hemodialysis clearance is substantial (2.62 ± 1.01 mL/min/kg), but measurable drug levels persist >50 hours after treatment with a half-life of 478 minutes in anuric patients 7, 5.
Monitoring Parameters
For Cyanide Poisoning:
- Blood pressure continuously during infusion (required) 1
- Monitor for 24-48 hours post-administration for recurrent symptoms 1
- Hemoglobin/hematocrit when treatment initiated 1
- Note: Standard pulse oximetry is unreliable due to methemoglobinemia from sodium nitrite 1
For Ototoxicity Prevention:
- Serial audiological evaluations per oncology protocol
- No specific monitoring for sodium thiosulfate itself required in this indication
For Calciphylaxis (Off-Label):
- Acid-base status closely after initiation - anion gap metabolic acidosis is a recognized complication, particularly in patients with chronic kidney disease 8, 5
- Wound healing assessment
- Electrolytes and renal function
Important Safety Considerations
Contraindications: None listed 1.
Warnings:
- May contain trace sodium sulfite impurities 1
- Risk of severe anion gap acidosis, especially in CKD patients (baseline creatinine considerations essential) 8
- Substantially excreted renally; greater risk of toxicity in renal impairment 1
- Breastfeeding not recommended 1
Common adverse effects: Hypotension, headache, disorientation, nausea 1, 9.
Drug incompatibilities: Cannot be mixed with hydroxocobalamin; use separate IV lines 1.
Clinical Pitfalls to Avoid
- Do not delay sodium thiosulfate in suspected cyanide poisoning while awaiting confirmatory testing 1
- Do not administer sodium thiosulfate before the 6-hour mark when using for ototoxicity prevention - this timing is critical for maintaining cisplatin efficacy 3
- Do not use in metastatic pediatric cancers for ototoxicity prevention due to potential survival concerns 3
- Do not assume oral bioavailability - only 7.6% bioavailable orally; IV route is essential 7
- Do not overlook acid-base monitoring in CKD patients receiving prolonged therapy 8